Price (delayed)
$1.3
Market cap
$239.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$323.46M
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines.
There are no recent dividends present for NKTR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.